Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3B 12-Week, Double -Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Varenicline Tartrate (CP-526,555) 1 mg BID for Smoking Cessation in Subjects With Schizophrenia and Schizoaffective Disorder.

NCT00644969 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00644969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00644969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3B 12-Week, Double -Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Varenicline Tartrate (CP-526,555) 1 mg BID for Smoking Cessation in Subjects With Schizophrenia and Schizoaffective Disorder.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2008
Completion date
April 30, 2010
Enrollment
128 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation